

Curriculum Vitae

Jeffrey Neal Joyce

July 1st, 2019

General Information

University address: Division of Research and Graduate Programs
College of Medicine
College of Medicine - Thrasher Building 1110-J
Florida State University
Tallahassee, Florida 32306-4300
Phone: 850/644-2190 [office]
Mobile: 480-201-3635

E-mail address: jeffrey.joyce@med.fsu.edu

Professional Preparation

- 1983 Ph.D., University of Florida, Gainesville. Major: Psychology. Physiological Psychology.
- 1977 B.S., University of Illinois, Champaign-Urbana, IL. Major: Psychology/Biology Cognate.

Nondegree Education and Training

- 1985–1986 NINCDS Postdoctoral Fellowship, Department of Psychobiology, University of California at Irvine.
- 1983–1985 NRSA Postdoctoral Training Grant, Postdoctoral Trainee, Department of Psychobiology, University of California at Irvine.

Professional Experience

- 2017–present Senior Associate Dean for Research and Graduate Programs, Division of Research and Graduate Programs, Professor of Biomedical Sciences, Florida State University College of Medicine.
- Oversees the basic science, translational, medical, and health services/public health research within the College of Medicine. Oversees a budget of more than \$5.6 million and 21 fulltime employees. The position reports directly to the Dean of the College of Medicine. The College of Medicine has a dynamic research agenda in areas that include Clinical Sciences, Biomedical Science, Geriatrics, Health Affairs, Behavioral Sciences and Social Medicine, the Autism Institute, and the Center for Translational Behavioral Science. The College also

support two university level cores: the Translational Science Laboratory and the MRI Facility. The College of Medicine admits 125 students per class with a full enrollment of 485 medical students, 14 Bridge M.S. students, 47 PhD students, and 11 postdocs. Oversees the basic science, translational, medical, and health services/public health research within the College of Medicine. Oversight and development of the interdisciplinary graduate programs. Oversight and development of the Network for Clinical Research and Training (NCRT) a statewide, collaborative, research network of faculty, community-based healthcare professionals and researchers that supports clinical and translational research. PI of CTSA award "*Together: Transforming and Translating Discovery to improve Health.*" Funded by University of Florida. A UF-FSU partnership to support translational research to improve health.

2012–2017

Vice President for Research, Professor of Pharmacology and Biosciences, Kansas City University of Medicine and Biosciences. A private university comprised of a College of Osteopathic Medicine, founded in 1916, and a College of Biosciences, Kansas City University of Medicine and Biosciences is the oldest medical school in Kansas City, Mo., the 11th largest in the nation, and a master's degree granting College of Biosciences.

- Administration & management for the Office of Research & Sponsored Programs. Responsible for management of all contract and sponsored research programs, academic and industry partnerships, IRB, IACUC, compliance operations, policies, audits, & financial oversight of research at KCUMB.
- Chair, Scholarly Activity & Faculty Development Committee for the Kansas City University of Medicine and Biosciences-Graduate Medical Education Consortium" ("KCU-GMEC"). A consortium formed through affiliation between KCUMB and freestanding hospitals and health-care institutions providing medical education to medical students, interns & residents in ACGME approved programs.
 - As the Institutional Official Oversees oversaw the development of current & long-term organizational goals and objectives as well as policies and procedures to ensure compliance with all applicable government and university policies as they relate to research & scholarship.

Highlights & Key Achievements

- Established Imaging Core (Leica TCS SP8 Confocal Microscope, Biotek Cytation 5 Cell Imaging Multi-Mode Reader stations), Biomarker Core (Protein Simple Wes, & Seahorse Extracellular flux analyzer), Vivarium and Aquatic animal facilities with OLAW assurance, Center for Neuromuscular Disease Laboratories
- February 2015: The Kansas City University of Medicine and Biosciences, the University of Missouri, Kansas City & the University of Kansas Medical Center established a research consortium among the 3 Kansas City-area institutions. The consortium brings together scientists and resources focused on the research of musculoskeletal disorders and diseases. This unique consortium was the first initiative of its kind in Kansas City and provides opportunities to combine the individual strengths & resources of the three health sciences schools to advance translational research.

2007–2012

Director, Department of Research, Maricopa Integrated Health System. Maricopa Integrated Health Service (MIHS) includes the Maricopa Hospital and Medical Center and eleven Family Health Centers located throughout the Phoenix metropolitan area. As an academic medical center it is home to 10 residency programs that provide training for approximately 60% of all physicians in the State of Arizona. The department was developed under my

leadership with oversight of all research grants and contracts, IRB, and research compliance, clinical research management.

- In 2007 developed and staffed two divisions within department to improve oversight of research compliance and financial accountability of Pharmaceutical Contracts and Compliance, and Academic Research and IRB Administration, ensuring proper management of all contract and sponsored research programs, academic research, human subject protection, research policies, audits, and financial oversight of research accounts.
- Established all clinical research operations and compliance, more than 60 clinical trials annually by 2010
- Collaborated with internal stakeholders to establish financial operations that were aligned with hospital operations and electronic medical record system. Co-Led with the Director of Government Reporting submission of indirect cost proposal to DHHS that led to a substantial increase in cost recovery in 2010.
- Established partnerships with leading academic institutions leading to a 2009- 2010 Memorandum of Understanding for Research and Graduate Education Partnership between Maricopa Integrated Health System and Arizona State University (ASU, Tempe, AZ)
- Instituted Technology Transfer agreements and IRB reciprocity agreements between MIHS and ASU, TGen (Translational Genomics Institute) and St. Joseph's Medical center for all research collaborations and contracts.
- Oversight of major research initiative that led to MIHS's participation in Arizona Biospecimen Consortium and Arizona Public Cord Blood Banking,
- Successful 160% increase in research projects, 250% increase in Sponsored contracts (e.g., clinical trials), and 200% increase in Federal grants in 5 years (2007-2012) •Number of active research projects (sponsored and resident-related) by 160% in 4 years.

1995–2006

Associate Director (Concurrent), Sun Health Research Institute. Established in 1987, it is a not-for-profit Institute within the Sun Health Corporation healthcare network (merged with Banner Health in 2008). The Institute is focused on transitional research in the neurodegenerative disorders of the aged, with emphasis in Alzheimer's disease, Parkinson's disease and chronic diseases in the aged.

- Co-managed research and development for the Institute (now Banner Sun Health Research Institute), facilitated development of grants and contracts, led development of strategic alliances with pharmaceutical companies (including IP/tech transfer). •Personally increased sponsorship from Pharmaceutical and Biotech companies 20-fold from 1995-2000. •Directly involved in recruitment of faculty that increased from 3 to 36 during the same 10 years, and stood at 36 Ph.D.s/M.D.s and 36 support staff.

1995–2006

Head (Concurrent), Arizona Parkinson's Disease Center, Sun Health Research Institute.

- Established the consortium that officially became the Arizona Parkinson's Disease Center by leading the strategic development and political action committee that developed State of Arizona Legislature funding for Parkinson's disease. Administrative Director for 3 clinical sites and 6 research laboratories (at two institutes) that constituted the Arizona Parkinson's Disease Center. •Oversaw all aspects of administration: budget, support staff, regulations (IRB), and fund procurement including service as the co-Director Parkinson's disease Brain Donor Program.

1995–2006

Senior Scientist and Head (Concurrent), Thomas H. Christopher Parkinson's Disease Research Center, Sun Health Research Institute. •Instituted the Center in 1995 with one laboratory, and expanded it to encompass four laboratories.

•Responsible for personnel recruitment, program development, fiscal management, and fund procurement. •The Center was awarded 11 research grants and contracts during that period, including four from pharmaceutical companies, three from the Michael J. Fox Foundation for Parkinson's disease Research, and three NIH-funded awards.

1989–1995

Associate Professor, Psychology and Neuroscience, University of Pennsylvania School of Medicine. Director of the Laboratory of Molecular Neurochemistry) Department of Psychiatry, CRB Psychiatry Research, directed research programs in developmental neurobiology and the molecular neurochemistry of the human brain, particularly related to neuropsychiatric and neurodegenerative illnesses.

•Led research laboratory operations including fiscal management, supervision of 18 scientists, and fund procurement. P.I. in several program project grants that crossed departmental boundaries in Pharmacology, Neurosurgery and Neuropathology. Awarded 11 grants including 2 NIH R01 grants. •Research Excellence: Awarded the prestigious Ziskind-Somerfeld Research Award for research into the biological substrates of schizophrenia by the Society for Biological Psychiatry in 1997. Identified as key contributor to policy change in mental health by Rand Corporation (Mental Health Retrosight, 2013, http://www.rand.org/pubs/research_briefs/RB9738.html).

1989–1990

Director, Psychiatry Research, University of Pennsylvania School of Medicine. •Directed and implemented the consolidation of 9 laboratories spread through the University Campus to one Research Building, inaugurating the comprehensive basic research programs of the Research Department in Psychiatry.

1986–1989

Research Assistant Professor, Pharmacology, University of Pennsylvania School of Medicine. •Faculty member of the School of Medicine in the Department of Pharmacology, Associate Member David Mahoney Institute of Neurological Sciences, Member Graduate Group in Pharmacology and Psychopharmacology training program •Taught graduate courses and managed laboratory operations including fiscal management, supervision of 8 staff, and fund procurement. Awarded 5 independent grants in three-year period.

Current Membership in Professional Organizations

GRAND (Group on Research Advancement and Development) Group FSU COM representative for Dean for Research and Dean for Clinical/Translational Research

GREAT ("Group on Graduate Research, Education, and Training of the Association of American Medical Colleges) Group FSU COM representative as Graduate Program and Postdoctorate Leaders Section leader

American College of Healthcare Executives

National Council of University Research Administrators

National Organization of Research Development Professionals

Public Responsibility in Medicine and Research
Society of Research Administrators (SRA) International
Health Care Compliance Association

Previous Membership in Professional Organizations (1986-2006)

American College of Neuropsychopharmacology
American Society for Pharmacology and Experimental Therapeutics
Annual Spring Brain Conference
Collegium Internationale Neuro-Psychopharmacologicum
European College of Neuropsychopharmacology
International Behavioral Neuroscience Society
International Society for Developmental Neuroscience
Society for Biological Psychiatry
Society for Neuroscience
The Movement Disorders Society

Teaching

Courses Taught

Health Sciences Seminar (IHS5935)

Doctoral Committee Chair

- # Goldsmith, S., graduate. (1993). *"Limbic dopamine D2 receptors: Interspecies differences and alterations in schizophrenia"*. [presented in fulfillment of Doctor of Philosophy degree, Department of Psychology, University of Illinois, Chicago]

Doctoral Committee Member

- # Presgraves, S., graduate. (2005). *"SHSY-5Y neuroblastoma cells a DA-phenotypic model system for studying D3 receptor agonist neuroprotection against MPP+-induced cell death"*. [Center for Molecular and Cellular Biology, Arizona State University, Tempe AZ (awarded, 2005)]
- # Frohna, P., graduate. (1995). *"The developmental plasticity of the dopamine systems: Effects of neonatal 6-hydroxydopamine lesions on the ontogenesis of the mesostriatal dopamine neurons and of striatal dopamine D1 and D2 receptors and mRNA"*. [Department of Pharmacology, University of Pennsylvania School of Medicine (awarded, 1995)]

Master's Committee Member

- # Der, T. C., graduate. (2007). *"Role of the serotonin system in modulating neurotoxicity of MPTP to dopamine neurons"*. [Graduate Program in Biology, Arizona State University, Tempe AZ (Awarded, 2007)]

Research and Original Creative Work

- Senior Executive within academia, championing innovation in research and graduate biomedical education. Adept at creating and managing strategic partnerships, developing large research programs, and supporting a strong collaborative culture within academic centers; consortium building between institutions, and history of leadership communicating the institution's transformative research and graduate education.
- Broad experience in research administration including sponsored research, clinical trials, IACUC, IRB, IBC, research compliance and IP licensing with highly analytical, strategic planning and project management skills managing large organizations and complex development projects in university, academic medical center and research institute environments.
- Impressive track record of success and building interdisciplinary research collaboration in multiple arenas and institutions. Personal success in translational research: neuroscience, neuropsychiatry and neurodegenerative disorders, with national and international speakerships, conferences, pharma, universities and other public forums. During 30 years of research publishing more than 110 original papers, reviews and book chapters, and awarded 8 NIH grants totaling over \$4 million, and an additional 17 grants and contracts from state, foundation and pharmaceutical industry totaling \$1.8 million.
- Faculty appointments at University of Pennsylvania School of Medicine (Pharmacology, Psychiatry), Arizona State University (Psychology, Biological and Health Systems Engineering), as well as adjunct appoints at the University of Arizona College of Medicine – Phoenix (Neurology and Psychiatry), with continuous involvement in graduate education.

Program of Research and/or Focus of Original Creative Work

- Impressive track record of success and leading translational research in multiple arenas with personal success in neuroscience, neuropsychiatry and neurodegenerative disorders, presenting with over 25 years of invited presentations at national and international meetings, universities and other public forums, publishing more than 110 original papers, reviews and book chapters, and awarded 8 NIH grants totaling over \$4 million, and an additional 17 grants and contracts from state, foundation and pharmaceutical industry totaling \$1.8 million
- Faculty appointments at University of Pennsylvania School of Medicine (Pharmacology, Psychiatry), Arizona State University (Psychology, Biological and Health Systems Engineering), as well as the University of Arizona College of Medicine – Phoenix (Neurology and Psychiatry), and involvement in graduate education
- Consultant to UpJohn Pharmacia and Pharmacia Corporation for 6 years in anti- Parkinsonian drug development before company was acquired by Pfizer. Consultant to Institute de Recherchés Servier (Suresnes, France) for five years for antipsychotic and anti-Parkinsonian drug development. Consultant to Pfizer Pharmaceuticals, Eli Lilly and Company, Schwarz Biosciences, Forest Laboratories, Gedeon Richter Plc (for Cariprazine)
- In 2007 I moved into leadership role in research administration and development.

Publications

Refereed Journal Articles

- # Joyce, J. N. (2013). Developing a Sustainable Research Culture in an Independent Academic Medical Center. *Journal of Research Administration*, 44(1), 75-90.
society publication of SRA International.
- # Joyce, J. N. (2011). Regulatory compliance for research in an academic medical center. *Compliance Today*, 13 (12), 29-37.
Health Care Compliance Association monthly.
- # Iarkov, A. V., Der, T. C., & Joyce, J. N. (2010). Age-related differences in MK-801 induced behaviors in dopamine D3 receptor knock out mice. *Eur J Pharmacol*, 627(1-3), 177-84. doi:10.1016/j.ejphar.2009.11.012
1879-0712 kov, Alex V , Terry C ce, Jeffrey N rnal Article earch Support, Non-U.S. Gov't herlands J Pharmacol. 2010 Feb 10;627(1-3):177-84. doi: 10.1016/j.ejphar.2009.11.012. Epub 2009 Nov 10.
- # Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010). Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. *J Clin Invest*, 120(5), 1774-85. doi:10.1172/jci41356
1558-8238 sa, Stephen M g, Tao , Youmei , Jian gen, Mehmet ce, Jeffrey N ama, Dean adas, Jayakumar go, Frank M rnal Article earch Support, Non-U.S. Gov't earch Support, U.S. Gov't, Non-P.H.S. ted States lin Invest. 2010 May;120(5):1774-85. doi: 10.1172/JCI41356. Epub 2010 Apr 19.
- # Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J. N., & Sidhu, A. (2010). Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. *Exp Neurol*, 225(1), 210-8. doi:10.1016/j.expneurol.2010.06.017
1090-2430 ls, Jonathan es, Jessica gerty, Thomas a, Valeriy ce, Jeffrey N hu, Anita AG028108-01A2/AG/NIA NIH HHS/United States NIA AGO28108/PHS HHS/United States AG028108/AG/NIA NIH HHS/United States AI062854/AI/NIAID NIH HHS/United States AG19610/AG/NIA NIH HHS/United States AG019610/AG/NIA NIH HHS/United States parative Study rnal Article earch Support, N.I.H., Extramural earch Support, Non-U.S. Gov't ted States Neurol. 2010 Sep;225(1):210-8. doi: 10.1016/j.expneurol.2010.06.017. Epub 2010 Jun 28.
- # Yarkov, A. V., Der, T. C., & Joyce, J. N. (2010). Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor. *Eur J Pharmacol*, 627(1-3), 167-72. doi:10.1016/j.ejphar.2009.10.068
1879-0712 kov, Alex V , Terry C ce, Jeffrey N rnal Article earch Support, Non-U.S. Gov't herlands J Pharmacol. 2010 Feb 10;627(1-3):167-72. doi: 10.1016/j.ejphar.2009.10.068. Epub 2009 Nov 10.

- # Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009). Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. *FASEB J*, *23*(9), 2820-30. doi:10.1096/fj.08-120410
- 1530-6860 a, Tetyana a, Valeriy ce, Jeffrey N hu, Anita AG028108-01A2/AG/NIA NIH HHS/United States NS045326-01A1/NS/NINDS NIH HHS/United States NS045326/NS/NINDS NIH HHS/United States AG028108/AG/NIA NIH HHS/United States AG028108/AG/NIA NIH HHS/United States NS45326/NS/NINDS NIH HHS/United States rnal Article earch Support, N.I.H., Extramural ted States EB J. 2009 Sep;23(9):2820-30. doi: 10.1096/fj.08-120410. Epub 2009 Apr 15.
- # Kufahl, P. R., Zavala, A. R., Singh, A., Thiel, K. J., Dickey, E. D., Joyce, J. N., & Neisewander, J. L. (2009). c-Fos expression associated with reinstatement of cocaine-seeking behavior by response-contingent conditioned cues. *Synapse*, *63*(10), 823-35. doi:10.1002/syn.20666
- 1098-2396 ahl, Peter R ala, Arturo R gh, Akanksha el, Kenneth J key, Erin D ce, Jeffrey N sewander, Janet L DA013649-05/DA/NIDA NIH HHS/United States 3649/DA/NIDA NIH HHS/United States DA021485-03/DA/NIDA NIH HHS/United States DA011064-11/DA/NIDA NIH HHS/United States DA013649/DA/NIDA NIH HHS/United States 21485/DA/NIDA NIH HHS/United States DA021485/DA/NIDA NIH HHS/United States 1064/DA/NIDA NIH HHS/United States DA011064/DA/NIDA NIH HHS/United States rnal Article earch Support, N.I.H., Extramural earch Support, Non-U.S. Gov't ted States apse. 2009 Oct;63(10):823-35. doi: 10.1002/syn.20666.
- # Mastroeni, D., Grover, A., Leonard, B., Joyce, J. N., Coleman, P. D., Kozik, B., Bellinger, D. L., & Rogers, J. (2009). Microglial responses to dopamine in a cell culture model of Parkinson's disease. *Neurobiol Aging*, *30*(11), 1805-17. doi:10.1016/j.neurobiolaging.2008.01.001
- 1558-1497 troeni, Diego ver, Andrew nard, Brian ce, Jeffrey N eman, Paul D ik, Brooke linger, Denise L ers, Joseph AG019610/AG/NIA NIH HHS/United States AG007367-15/AG/NIA NIH HHS/United States -7367/PHS HHS/United States AG19610/AG/NIA NIH HHS/United States rnal Article earch Support, N.I.H., Extramural earch Support, Non-U.S. Gov't ted States robiol Aging. 2009 Nov;30(11):1805-17. doi: 10.1016/j.neurobiolaging.2008.01.001. Epub 2008 Mar 5.
- # Bychkov, E. R., Gurevich, V. V., Joyce, J. N., Benovic, J. L., & Gurevich, E. V. (2008). Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. *Neurobiology of Aging*, *29*(3), 379-396. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000253436400007> doi:10.1016/j.neurobiolaging.2006.10.012
- Gurevich, Vsevolod/A-3236-2008 evich, Vsevolod/0000-0002-3950-5351.
- # Zavala, A. R., Osredkar, T., Joyce, J. N., & Neisewander, J. L. (2008). Upregulation of Arc mRNA expression in the prefrontal cortex following cue-induced reinstatement of extinguished cocaine-seeking behavior. *Synapse*, *62*(6), 421-31. doi:10.1002/syn.20502
- Zavala, Arturo R edkar, Tracy ce, Jeffrey N sewander, Janet L DA013649/DA/NIDA NIH HHS/United States DA013649-05/DA/NIDA NIH HHS/United States 13649/DA/NIDA NIH HHS/United States rnal Article earch Support, N.I.H., Extramural earch Support, Non-U.S. Gov't ted States apse. 2008 Jun;62(6):421-31. doi: 10.1002/syn.20502.

- # Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007). PIB is a non-specific imaging marker of amyloid-beta (A beta) peptide-related cerebral amyloidosis. *Brain*, *130*, 2607-2615. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000250039500014> doi:10.1093/brain/awm191
- 10.
- # Nakadate, K., Noda, T., Sakakibara, S., Kumamoto, K., Matsuura, T., Joyce, J. N., & Ueda, S. (2006). Progressive dopaminergic neurodegeneration of substantia nigra in the zitter mutant rat. *Acta Neuropathologica*, *112*(1), 64-73. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000238630800008> doi:10.1007/s00401-006-0058-8
- 14.
- # Yoshimoto, K., Nishimura, A., Hattori, H., Joyce, J. N., Yoshida, T., Hioki, C., Kogure, A., & Ueda, S. (2006). In vivo brain microdialysis studies on the striatal dopamine and serotonin release in zitter mutant rats. *Mechanisms of Ageing and Development*, *127*(7), 628-632. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000238607900005> doi:10.1016/j.mad.2006.02.008
- 1.
- # Ueda, S., Sakakibara, S., Nakadate, K., Noda, T., Shinoda, M., & Joyce, J. N. (2005). Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E. *Neurosci Lett*, *380*(3), 252-6. doi:10.1016/j.neulet.2005.01.053
- Ueda, Shuichi akibara, Shin-ichi adate, Kazuhiko a, Takahiro noda, Motoo ce, Jeffrey N rnal Article land rosci Lett. 2005 Jun 3;380(3):252-6. Epub 2005 Feb 8.
- # Beach, T. G., Walker, D. G., Sue, L. I., Newell, A., Adler, C. C., & Joyce, J. N. (2004). Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. *J Neuropathol Exp Neurol*, *63*(4), 329-37.
- Beach, Thomas G ker, Douglas G , Lucia I ell, Amanda er, Charles C ce, Jeffrey N parative Study rnal Article earch Support, Non-U.S. Gov't land europathol Exp Neurol. 2004 Apr;63(4):329-37.
- # Dluzen, D. E., McDermott, J. L., Anderson, L. I., Kucera, J., Joyce, J. N., Osredkar, T., & Walro, J. M. (2004). Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice. *Neuroscience*, *128*(1), 201-208. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action>

=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000223955100020 doi:10.1016/j.neuroscience.2004.06.032

16.

- # Joyce, J. N., Der, T. C., Renish, L., Osredkar, T., Hagner, D., Reploge, M., Sakakibara, S., & Ueda, S. (2004). Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment. *Exp Neurol*, *187*(1), 178-89. doi:10.1016/j.expneurol.2004.01.012
- Joyce, Jeffrey N, T C ish, Lynn edkar, Tracy ner, Diane loge, Maria akibara, Shinichi a, Shuichi 0669/NS/NINDS NIH HHS/United States rnal Article earch Support, U.S. Gov't, P.H.S. ted States Neurol. 2004 May;187(1):178-89.
- # Joyce, J. N., Renish, L., Osredkar, T., Walro, J. M., Kucera, J., & Dluzen, D. E. (2004). Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations. *Synapse*, *52*(1), 11-9. doi:10.1002/syn.10309
- Joyce, Jeffrey N ish, Lynn edkar, Tracy ro, Jon M era, Jan zen, Dean E 0699/NS/NINDS NIH HHS/United States rnal Article earch Support, Non-U.S. Gov't earch Support, U.S. Gov't, P.H.S. ted States apse. 2004 Apr;52(1):11-9.
- # Joyce, J. N., Woolsey, C., Ryoo, H., Borwege, S., & Hagner, D. (2004). Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. *BMC Biol*, *2*, 22. doi:10.1186/1741-7007-2-22
- 1741-7007 ce, Jeffrey N lsey, Cheryl o, Han wege, Sabine ner, Diane NS040669/NS/NINDS NIH HHS/United States 0669/NS/NINDS NIH HHS/United States rnal Article earch Support, N.I.H., Extramural earch Support, Non-U.S. Gov't earch Support, U.S. Gov't, P.H.S. land Biol. 2004 Oct 11;2:22.
- # Millan, M. J., Di Cara, B., Hill, M., Jackson, M., Joyce, J. N., Brotchie, J., McGuire, S., Crossman, A., Smith, L., Jenner, P., Gobert, A., Peglion, J. L., & Brocco, M. (2004). S32504, a novel naphthoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. *J Pharmacol Exp Ther*, *309*(3), 921-35. doi:10.1124/jpet.103.062414
- Millan, Mark J Cara, Benjamin l, Michael kson, Michael ce, Jeffrey N tchie, Jonathan uire, Steve ssman, Alan th, Lance ner, Peter ert, Alain lion, Jean-Louis cco, Mauricette parative Study rnal Article ted States harmacol Exp Ther. 2004 Jun;309(3):921-35. Epub 2004 Feb 20.
- # Neisewander, J. L., Fuchs, R. A., Tran-Nguyen, L. T., Weber, S. M., Coffey, G. P., & Joyce, J. N. (2004). Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. *Neuropsychopharmacology*, *29*(8), 1479-87. doi:10.1038/sj.npp.1300456
- Neisewander, Janet L hs, Rita A n-Nguyen, Ly T L er, Suzanne M fey, Greg P ce, Jeffrey N 5816/DA/NIDA NIH HHS/United States 1064/DA/NIDA NIH HHS/United States 0699/NS/NINDS NIH HHS/United States rnal Article earch Support, Non-U.S. Gov't earch Support, U.S. Gov't, P.H.S. land ropsychopharmacology. 2004 Aug;29(8):1479-87.

- # Presgraves, S. P., Ahmed, T., Borwege, S., & Joyce, J. N. (2004). Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. *Neurotox Res*, 5(8), 579-98.
- Presgraves, Steven P ed, Tariq wege, Sabine ce, Jeffrey N 0669/NS/NINDS NIH HHS/United States rnal Article earch Support, Non-U.S. Gov't earch Support, U.S. Gov't, P.H.S. ted States rotox Res. 2004;5(8):579-98.
- # Presgraves, S. P., Borwege, S., Millan, M. J., & Joyce, J. N. (2004). Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. *Exp Neurol*, 190(1), 157-70. doi:10.1016/j.expneurol.2004.06.021
- Presgraves, Steve P wege, Sabine lan, Mark J ce, Jeffrey N 40669/NS/NINDS NIH HHS/United States rnal Article earch Support, Non-U.S. Gov't earch Support, U.S. Gov't, P.H.S. ted States Neurol. 2004 Nov;190(1):157-70.
- # Joyce, J. N., Presgraves, S., Renish, L., Borwege, S., Osredkar, T., Hagner, D., Replogle, M., PazSoldan, M., & Millan, M. J. (2003). Neuroprotective effects of the novel D-3/D-2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. *Experimental Neurology*, 184(1), 393-407. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000186804800041> doi:10.1016/s0014-4886(03)00353-4
- Paz Soldan, M. Mateo/0000-0003-0521-7789.
- # Yarkov, A. V., Hanger, D., Replogle, M., & Joyce, J. N. (2003). Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D-3 receptor knockout mice. *Pharmacology Biochemistry and Behavior*, 76(3-4), 551-562. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000187351300020> doi:10.1016/j.pbb.2003.09.011
- 12, Yarkov, Alex V ger, Diane loge, Maria ce, Jeffrey N 40669/NS/NINDS NIH HHS/United States rnal Article earch Support, U.S. Gov't, P.H.S. ted States rmacol Biochem Behav. 2003 Dec;76(3-4):551-62.
- # Adler, C. H., Hentz, J. G., Joyce, J. N., Beach, T., & Caviness, J. N. (2002). Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. *Parkinsonism Relat Disord*, 9(2), 103-10.
- Adler, Charles H tz, Joseph G ce, Jeffrey N ch, Thomas iness, John N parative Study luation Studies rnal Article earch Support, Non-U.S. Gov't land kinsonism Relat Disord. 2002 Dec;9(2):103-10.
- # Joyce, J. N., Ryoo, H. L., Beach, T. B., Caviness, J. N., Stacy, M., Gurevich, E. V., Reiser, M., & Adler, C. H. (2002). Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. *Brain Research*, 955(1-2),

138-152. Retrieved from

<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000179424800016> doi:10.1016/s0006-8993(02)03396-6

47.

- # Gurevich, E. V., Robertson, R. T., & Joyce, J. N. (2001). Thalamo-cortical afferents control transient expression of the dopamine D-3 receptor in the rat somatosensory cortex. *Cerebral Cortex*, *11*(8), 691-701. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000170044400002> doi:10.1093/cercor/11.8.691

8.

- # Joyce, J. N. (2001). D-2 but not D-3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period. *Synapse*, *40*(2), 137-144. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000167552100006> doi:10.1002/syn.1035

36.

- # Joyce, J. N. (2001). Dopamine D-3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. *Pharmacology & Therapeutics*, *90*(2-3), 231-259. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000171427800004> doi:10.1016/s0163-7258(01)00139-5

181.

- # Joyce, J. N., Ryoo, H., Gurevich, E. V., Adler, C., & Beach, T. (2001). Ventral striatal D-3 receptors and Parkinson's disease. *Parkinsonism & Related Disorders*, *7*(3), 225-230. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000168921200010> doi:10.1016/s1353-8020(00)00060-2

14.

- # Joyce, J. N. (2001). Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. *Pharmacology and Therapeutics*, *90*(2-3), 231-259. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action>

=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BIOSIS:PREV200100522137

0.

- # Gurevich, E. V., Himes, W., & Joyce, J. N. (2000). Dopamine D-3 receptor is selectively and transiently expressed in the developing whisker barrel cortex of the rat. *Journal of Comparative Neurology*, 420(1), 35-51. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000086207000003> doi:10.1002/(sici)1096-9861(20000424)420:1[3

12.

- # Gurevich, E. V., Kordower, J. H., & Joyce, J. N. (2000). Ontogeny of the dopamine D-2 receptor mRNA expressing cells in the human hippocampal formation and temporal neocortex. *Journal of Chemical Neuroanatomy*, 20(3-4), 307-325. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000167117200011> doi:10.1016/s0891-0618(00)00108-3

8.

- # Joyce, J. N., Yoshimoto, K., & Ueda, S. (2000). The zitter mutant rat exhibits loss of D3 receptors with degeneration of the dopamine system. *Neuroreport*, 11(10), 2173-2175. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000088282700022> doi:10.1097/00001756-200007140-00022

11.

- # Gurevich, E. V., Himes, J. W., & Joyce, J. N. (1999). Developmental regulation of expression of the D-3 dopamine receptor in rat nucleus accumbens and Islands of Calleja. *Journal of Pharmacology and Experimental Therapeutics*, 289(1), 587-598. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000079365700075>

24.

- # Gurevich, E. V., & Joyce, J. N. (1999). Distribution of dopamine D-3 receptor expressing neurons in the human forebrain: Comparison with D-2 receptor expressing neurons. *Neuropsychopharmacology*, 20(1), 60-80. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000077145100008> doi:10.1016/s0893-133x(98)00066-9

285.

- # Joyce, J. N., & Gurevich, E. V. (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. *Neuropsychopharmacol*, 20, 60-80. Retrieved from [http://dx.doi.org/10.1016/S0893-133X\(98\)00066-9](http://dx.doi.org/10.1016/S0893-133X(98)00066-9) doi:10.1016/S0893-133X(98)00066-9
- # Ma, S. Y., Ciliax, B. J., Stebbins, G., Jaffar, S., Joyce, J. N., Cochran, E. J., Kordower, J. H., Mash, D. C., Levey, A. I., & Mufson, E. J. (1999). Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. *Journal of Comparative Neurology*, 409(1), 25-37. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000080485200003> doi:10.1002/(sici)1096-9861(19990621)409:1[2
Levey, Allan/F-2104-2011 ey, Allan/0000-0002-3153-502X; Kazmi, Syed/0000-0002-1577-8419.
- # Neal-Beliveau, B. S., & Joyce, J. N. (1999). Timing: A critical determinant of the functional consequences of neonatal 6-OHDA lesions. *Neurotoxicology and Teratology*, 21(2), 129-140. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000079260400003> doi:10.1016/s0892-0362(98)00044-0
7.
- # Joyce, J. N., Murray, A. M., Hurtig, H. I., Gottlieb, G. L., & Trojanowski, J. Q. (1998). Loss of dopamine D-2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. *Neuropsychopharmacology*, 19(6), 472-480. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000076423600003> doi:10.1016/s0893-133x(98)00044-x
28.
- # Joyce, J. N., Myers, A. J., & Gurevich, E. (1998). Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. *Brain Research*, 784(1-2), 7-17. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000072586800002> doi:10.1016/s0006-8993(97)01005-6
Myers, Amanda/B-1796-2010 rs, Amanda/0000-0002-3100-9396.
- # Neal-Beliveau, B. S., & Joyce, J. N. (1998). Behavioral responsivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. *Developmental Psychobiology*, 32(4), 313-326. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000073477300006>
5.

- # Rioux, L., Nissanov, J., & Joyce, J. N. (1998). Increased number of I-125 BH-substance P receptors in schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 22(8), 1295-1299. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000077241600006> doi:10.1016/s0278-5846(98)00084-0
- 9.
- # Ryoo, H. L., Pierrotti, D., & Joyce, J. N. (1998). Dopamine D-3 receptor is decreased and D-2 receptor is elevated in the striatum of Parkinson's disease. *Movement Disorders*, 13(5), 788-797. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000075898900004> doi:10.1002/mds.870130506
- 92.
- # Thomas, W. S., Neal-Beliveau, B. S., & Joyce, J. N. (1998). There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum. *Brain research. Developmental brain research*, 111(1), 99-106. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=MEDLINE:9804909>
- 0.
- # Frohna, P. A., NealBeliveau, B. S., & Joyce, J. N. (1997). Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions. *Synapse*, 25(3), 293-305. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997WM01400009>
- 18.
- # Goldsmith, S. K., Shapiro, R. M., & Joyce, J. N. (1997). Disrupted pattern of D-2 dopamine receptors in the temporal lobe in schizophrenia - A postmortem study. *Archives of General Psychiatry*, 54(7), 649-658. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997XK68700007>
- 64.
- # Gurevich, E. V., Bordelon, Y., Shapiro, R. M., Arnold, S. E., Gur, R. E., & Joyce, J. N. (1997). Mesolimbic dopamine D-3 receptors and use of antipsychotics in patients with schizophrenia - A postmortem study. *Archives of General Psychiatry*, 54(3), 225-232. Retrieved from

<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997WP35500005>

Arnold, Steven/J-7546-2012.

- # Gurevich, E. V., & Joyce, J. N. (1997). Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. *Biological Psychiatry*, 42(7), 529-545. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997XX20400001> doi:10.1016/s0006-3223(97)00321-1
141.
- # Gurevich, E. V., Kordower, J., & Joyce, J. N. (1997). Dopamine D2 receptor mRNA is expressed in maturing neurons of the human hippocampal and subicular fields. *Neuroreport*, 8(16), 3605-3610. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997YF19700042> doi:10.1097/00001756-199711100-00037
6.
- # Joyce, J. N., & MeadorWoodruff, J. H. (1997). Linking the family of D-2 receptors to neuronal circuits in human brain: Insights into schizophrenia. *Neuropsychopharmacology*, 16(6), 375-384. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997WZ78800001> doi:10.1016/s0893-133x(96)00276-x
87.
- # Joyce, J. N., Smutzer, G., Whitty, C. J., Myers, A., & Bannon, M. J. (1997). Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. *Movement Disorders*, 12(6), 885-897. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997YF94500008> doi:10.1002/mds.870120609
Myers, Amanda/B-1796-2010 rs, Amanda/0000-0002-3100-9396; Smutzer, Gregory/0000-0002-4036-5667.
- # Rioux, L., Frohna, P. A., Joyce, J. N., & Schneider, J. S. (1997). The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. *Movement Disorders*, 12(2), 148-158. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action>

=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997WP4820002 doi:10.1002/mds.870120204

42.

- # Goldsmith, S. K., & Joyce, J. N. (1996). Dopamine D2 receptors are organized in bands in normal human temporal cortex. *Neuroscience*, 74(2), 435-451. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1996VC75500014> doi:10.1016/0306-4522(96)00132-7

39.

- # Gurevich, E. V., & Joyce, J. N. (1996). Comparison of H-3 paroxetine and H-3 cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. *Neuropsychopharmacology*, 14(5), 309-323. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1996UF56100002> doi:10.1016/0893-133x(95)00139-5

54.

- # Solbrig, M. V., Koob, G. F., Joyce, J. N., & Lipkin, W. I. (1996). A neural substrate of hyperactivity in Borna disease: Changes in brain dopamine receptors. *Virology*, 222(2), 332-338. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1996VD70700004> doi:10.1006/viro.1996.0430

koob, george/P-8791-2016.

- # Frohna, P. A., Nealbeliveau, B. S., & Joyce, J. N. (1995). NEONATAL 6-HYDROXYDOPAMINE LESIONS LEAD TO OPPOSING CHANGES IN THE LEVELS OF DOPAMINE-RECEPTORS AND THEIR MESSENGER-RNAS. *Neuroscience*, 68(2), 505-518. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1995RL98300022> doi:10.1016/0306-4522(95)00155-c

16.

- # Frohna, P. A., Rothblat, D. S., Joyce, J. N., & Schneider, J. S. (1995). ALTERATIONS IN DOPAMINE UPTAKE SITES AND D1 AND D2 RECEPTORS IN CATS SYMPTOMATIC FOR AND RECOVERED FROM EXPERIMENTAL PARKINSONISM. *Synapse*, 19(1), 46-55. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1995QH90100006> doi:10.1002/syn.890190107

27.

- # Goldsmith, S. K., & Joyce, J. N. (1995). ALTERATIONS IN HIPPOCAMPAL MOSSY FIBER PATHWAY IN SCHIZOPHRENIA AND ALZHEIMERS-DISEASE. *Biological Psychiatry*, 37(2), 122-126. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1995QC58400008> doi:10.1016/0006-3223(94)00200-m
41.
- # Murray, A. M., Weihmueller, F. B., Marshall, J. F., Hurtig, H. I., Gottlieb, G. L., & Joyce, J. N. (1995). DAMAGE TO DOPAMINE SYSTEMS DIFFERS BETWEEN PARKINSONS-DISEASE AND ALZHEIMERS-DISEASE WITH PARKINSONISM. *Annals of Neurology*, 37(3), 300-312. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1995QM19500005> doi:10.1002/ana.410370306
89.
- # Goldsmith, S. K., & Joyce, J. N. (1994). DOPAMINE D2 RECEPTOR EXPRESSION IN HIPPOCAMPUS AND PARAHIPPOCAMPAL CORTEX OF RAT, CAT, AND HUMAN IN RELATION TO TYROSINE HYDROXYLASE-IMMUNOREACTIVE FIBERS. *Hippocampus*, 4(3), 354-373. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1994PN13000017> doi:10.1002/hipo.450040318
66.
- # Lexow, N., Joyce, J. N., Kim, S. J., Phillips, J., Casanova, M. F., Bird, E. D., Kleinman, J. E., & Winokur, A. (1994). ALTERATIONS IN TRH RECEPTORS IN TEMPORAL-LOBE OF SCHIZOPHRENICS - A QUANTITATIVE AUTORADIOGRAPHIC STUDY. *Synapse*, 18(4), 315-327. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1994QH89900006> doi:10.1002/syn.890180407
8.
- # Murray, A. M., Ryoo, H. L., Gurevich, E., & Joyce, J. N. (1994). LOCALIZATION OF DOPAMINE D-3 RECEPTORS TO MESOLIMBIC AND D-2 RECEPTORS TO MESOSTRIATAL REGIONS OF HUMAN FOREBRAIN. *Proceedings of the National Academy of Sciences of the United States of America*, 91(23), 11271-11275. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1994PQ93800106> doi:10.1073/pnas.91.23.11271
234.

- # Ryoo, H. L., & Joyce, J. N. (1994). LOSS OF DOPAMINE D2 RECEPTORS VARIES ALONG THE ROSTROCAUDAL AXIS OF THE HIPPOCAMPAL COMPLEX IN ALZHEIMERS-DISEASE. *Journal of Comparative Neurology*, 348(1), 94-110. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1994PH36200004> doi:10.1002/cne.903480105
- 31.
- # Ulas, J., Weihmuller, F. B., Brunner, L. C., Joyce, J. N., Marshall, J. F., & Colman, C. W. (1994). SELECTIVE INCREASE OF NMDA-SENSITIVE GLUTAMATE BINDING IN THE STRIATUM OF PARKINSONS-DISEASE, ALZHEIMERS-DISEASE, AND MIXED PARKINSONS-DISEASE ALZHEIMERS-DISEASE PATIENTS - AN AUTORADIOGRAPHIC STUDY. *Journal of Neuroscience*, 14(11), 6317-6324. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1994PQ38100002>
- 1.
- # Frohna, P. A., Nealbeliveau, B. S., & Joyce, J. N. (1993). NEONATAL 6-OHDA LESIONS UP-REGULATE ADULT EXPRESSION OF TYROSINE-HYDROXYLASE MESSENGER-RNA. *Neuroreport*, 4(9), 1095-1098. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993LR95400007>
- 7.
- # Joyce, J. N. (1993). DIFFERENTIAL RESPONSE OF STRIATAL DOPAMINE AND MUSCARINIC CHOLINERGIC RECEPTOR SUBTYPES TO THE LOSS OF DOPAMINE .3. RESULTS IN PARKINSONS-DISEASE CASES. *Brain Research*, 600(1), 156-160. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993KG54000021> doi:10.1016/0006-8993(93)90414-i
- 34.
- # Joyce, J. N. (1993). THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA - LIMBIC INTERACTIONS WITH SEROTONIN AND NOREPINEPHRINE. *Psychopharmacology*, 112(1), S16-S34. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993LV40600003> doi:10.1007/bf02245004
- S.

- # Joyce, J. N., Kaeger, C., Ryoo, H., & Goldsmith, S. (1993). DOPAMINE D2 RECEPTORS IN THE HIPPOCAMPUS AND AMYGDALA IN ALZHEIMERS-DISEASE. *Neuroscience Letters*, *154(1-2)*, 171-174. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993LF89000044> doi:10.1016/0304-3940(93)90199-u
36.
- # Joyce, J. N., Shane, A., Lexow, N., Winokur, A., Casanova, M. F., & Kleinman, J. E. (1993). SEROTONIN UPTAKE SITES AND SEROTONIN RECEPTORS ARE ALTERED IN THE LIMBIC SYSTEM OF SCHIZOPHRENICS. *Neuropsychopharmacology*, *8(4)*, 315-336. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993LD16100003>
291.
- # Nealbeliveau, B. S., & Joyce, J. N. (1993). D(1) AND D(2) DOPAMINE-RECEPTORS DO NOT UP-REGULATE IN RESPONSE TO NEONATAL INTRASTRIATAL 6-HYDROXYDOPAMINE LESIONS. *Neuroscience Letters*, *160(1)*, 77-80. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993LX94600020> doi:10.1016/0304-3940(93)90917-a
15.
- # Nealbeliveau, B. S., Joyce, J. N., & Lucki, I. (1993). SEROTONERGIC INVOLVEMENT IN HALOPERIDOL-INDUCED CATALEPSY. *Journal of Pharmacology and Experimental Therapeutics*, *265(1)*, 207-217. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993KY06600030>
129.
- # Rioux, L., & Joyce, J. N. (1993). SUBSTANCE-P RECEPTORS ARE DIFFERENTIALY AFFECTED IN PARKINSONS AND ALZHEIMERS-DISEASE. *Journal of Neural Transmission-Parkinsons Disease and Dementia Section*, *6(3)*, 199-210. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1993MN60500005> doi:10.1007/bf02260922
14.

- # Joyce, J. N., Lexow, N., Kim, S. J., Artymyshyn, R., Senzon, S., Lawrence, D., Cassanova, M. F., Kleinman, J. E., Bird, E. D., & Winokur, A. (1992). DISTRIBUTION OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN HUMAN POSTMORTEM BRAIN - ALTERATIONS IN LIMBIC REGIONS OF SCHIZOPHRENICS. *Synapse*, *10*(3), 228-246. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1992HF84300005> doi:10.1002/syn.890100306
61.
- # Kleinman, J. E., Laruelle, M., Joyce, J. N., & Casanova, M. F. (1992). Abnormalities of serotonergic neural transmission in prefrontal cortex in schizophrenia. *Clinical neuropharmacology*, *15 Suppl 1 Pt A*, 397A-398A. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=MEDLINE:1323396>
0.
- # Murray, A. M., Ryoo, H., & Joyce, J. N. (1992). VISUALIZATION OF DOPAMINE-D(3)-LIKE RECEPTORS IN HUMAN BRAIN WITH 125I EPIDEPRIDE. *European Journal of Pharmacology-Molecular Pharmacology Section*, *227*(4), 443-445. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1992KA02500013> doi:10.1016/0922-4106(92)90164-q
41.
- # Neal, B. S., & Joyce, J. N. (1992). NEONATAL 6-OHDA LESIONS DIFFERENTIALLY AFFECT STRIATAL D1-RECEPTORS AND D2-RECEPTORS. *Synapse*, *11*(1), 35-46. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1992HQ75700005> doi:10.1002/syn.890110106
32.
- # Joyce, J. N. (1991). DIFFERENTIAL RESPONSE OF STRIATAL DOPAMINE AND MUSCARINIC CHOLINERGIC RECEPTOR SUBTYPES TO THE LOSS OF DOPAMINE .1. EFFECTS OF INTRANIGRAL OR INTRACEREBROVENTRICULAR 6-HYDROXYDOPAMINE LESIONS OF THE MESOSTRIATAL DOPAMINE SYSTEM. *Experimental Neurology*, *113*(3), 261-276. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1991GC10100001> doi:10.1016/0014-4886(91)90016-6
73.

- # Joyce, J. N. (1991). DIFFERENTIAL RESPONSE OF STRIATAL DOPAMINE AND MUSCARINIC CHOLINERGIC RECEPTOR SUBTYPES TO THE LOSS OF DOPAMINE .2. EFFECTS OF 6-HYDROXYDOPAMINE OR COLCHICINE MICROINJECTIONS INTO THE VTA OR RESERPINE TREATMENT. *Experimental Neurology*, 113(3), 277-290. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1991GC10100002> doi:10.1016/0014-4886(91)90017-7
49.
- # Joyce, J. N., Janowsky, A., & Neve, K. A. (1991). CHARACTERIZATION AND DISTRIBUTION OF I-125 EPIDEPRIDE BINDING TO DOPAMINE-D2 RECEPTORS IN BASAL GANGLIA AND CORTEX OF HUMAN BRAIN. *Journal of Pharmacology and Experimental Therapeutics*, 257(3), 1253-1263. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1991FQ59300047>
88.
- # Neal, B. S., & Joyce, J. N. (1991). Dopamine D1 receptor behavioral responsivity following selective lesions of the striatal patch compartment during development. *Brain research. Developmental brain research*, 60(2), 105-13. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=MEDLINE:1832593>
0.
- # Rao, P. A., Molinoff, P. B., & Joyce, J. N. (1991). ONTOGENY OF DOPAMINE D1 AND D2 RECEPTOR SUBTYPES IN RAT BASAL GANGLIA - A QUANTITATIVE AUTORADIOGRAPHIC STUDY. *Developmental Brain Research*, 60(2), 161-177. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1991FW85000008> doi:10.1016/0165-3806(91)90045-k
131.
- # Joyce, J. N., & Hurtig, H. (1990). Differential regulation of striatal dopamine D1 and D2 receptor systems in Parkinson's disease and effects of adrenal medullary transplant. *Progress in brain research*, 82, 699-706. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=MEDLINE:2290973>
0.

- # Joyce, J. N., & Hurtig, H. (1990). DIFFERENTIAL REGULATION OF STRIATAL DOPAMINE-D1 AND DOPAMINE-D2 RECEPTOR SYSTEMS IN PARKINSONS-DISEASE AND EFFECTS OF ADRENAL-MEDULLARY TRANSPLANT. *Progress in Brain Research*, 82, 699-706. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1990ED43100079>
0.
- # Lowenstein, P. R., Joyce, J. N., Coyle, J. T., & Marshall, J. F. (1990). STRIOSOMAL ORGANIZATION OF CHOLINERGIC AND DOPAMINERGIC UPTAKE SITES AND CHOLINERGIC-M1 RECEPTORS IN THE ADULT HUMAN STRIATUM - A QUANTITATIVE RECEPTOR AUTORADIOGRAPHIC STUDY. *Brain Research*, 510(1), 122-126. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1990CT05200018> doi:10.1016/0006-8993(90)90736-u
34.
- # Hurtig, H., Joyce, J. N., Sladek, J. R., & Trojanowski, J. (1989). Post mortem analysis of autograft from adrenal medulla to caudate in a patient with Parkinson's disease. *Annal. Neurol*, 25, 607-614.
- # Joyce, J. N., Gibbs, R. B., Cotman, C. W., & Marshall, J. F. (1989). REGULATION OF MUSCARINIC RECEPTORS IN HIPPOCAMPUS FOLLOWING CHOLINERGIC DENERVATION AND REINNERVATION BY SEPTAL AND STRIATAL TRANSPLANTS. *Journal of Neuroscience*, 9(8), 2776-2791. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1989AL51800014>
53.
- # Marshall, J. F., Navarrete, R., & Joyce, J. N. (1989). DECREASED STRIATAL-D1 BINDING DENSITY FOLLOWING MESOTELENCEPHALIC 6-HYDROXYDOPAMINE INJECTIONS - AN AUTORADIOGRAPHIC ANALYSIS. *Brain Research*, 493(2), 247-257. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1989AG87000006> doi:10.1016/0006-8993(89)91160-8
105.
- # Joyce, J. N., Lexow, N., Bird, E., & Winokur, A. (1988). ORGANIZATION OF DOPAMINE D1 AND D2 RECEPTORS IN HUMAN STRIATUM - RECEPTOR AUTORADIOGRAPHIC STUDIES IN HUNTINGTONS-DISEASE AND SCHIZOPHRENIA. *Synapse*, 2(5), 546-557. Retrieved from

<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1988Q426800010> doi:10.1002/syn.890020511

144.

- # Marshall, J. F., & Joyce, J. N. (1988). BASAL GANGLIA DOPAMINE RECEPTOR AUTORADIOGRAPHY AND AGE-RELATED MOVEMENT-DISORDERS. *Annals of the New York Academy of Sciences*, 515, 215-225. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1988R735600016> doi:10.1111/j.1749-6632.1988.tb32988.x

17.

- # Joyce, J. N., & Marshall, J. F. (1987). QUANTITATIVE AUTORADIOGRAPHY OF DOPAMINE-D2 SITES IN RAT CAUDATE-PUTAMEN - LOCALIZATION TO INTRINSIC NEURONS AND NOT TO NEOCORTICAL AFFERENTS. *Neuroscience*, 20(3), 773-795. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1987H553500006> doi:10.1016/0306-4522(87)90240-5

155.

- # Rhodes, K. J., Joyce, J. N., Sapp, D. W., & Marshall, J. F. (1987). H-3 HEMICHOLINIUM-3 BINDING IN RABBIT STRIATUM - CORRESPONDENCE WITH PATCHY ACETYLCHOLINESTERASE STAINING AND A METHOD FOR QUANTIFYING STRIATAL COMPARTMENTS. *Brain Research*, 412(2), 400-404. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1987H589300025> doi:10.1016/0006-8993(87)91151-6

20.

- # Joyce, J. N., Loeschen, S. K., Sapp, D. W., & Marshall, J. F. (1986). AGE-RELATED REGIONAL LOSS OF CAUDATE-PUTAMEN DOPAMINE-RECEPTORS REVEALED BY QUANTITATIVE AUTORADIOGRAPHY. *Brain Research*, 378(1), 158-163. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1986D253000019> doi:10.1016/0006-8993(86)90298-2

47.

- # Joyce, J. N., Marshall, J. F., Bankiewicz, K. S., Kopin, I. J., & Jacobowitz, D. M. (1986). HEMIPARKINSONISM IN A MONKEY AFTER UNILATERAL INTERNAL CAROTID-ARTERY INFUSION OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IS ASSOCIATED WITH REGIONAL IPSILATERAL CHANGES IN STRIATAL DOPAMINE D-2 RECEPTOR DENSITY.

Brain Research, 382(2), 360-364. Retrieved from
<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1986E069400015> doi:10.1016/0006-8993(86)91345-4

43.

- # Joyce, J. N., Sapp, D. W., & Marshall, J. F. (1986). HUMAN STRIATAL DOPAMINE-RECEPTORS ARE ORGANIZED IN COMPARTMENTS. *Proceedings of the National Academy of Sciences of the United States of America*, 83(20), 8002-8006. Retrieved from
<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1986E536100093> doi:10.1073/pnas.83.20.8002

119.

- # Vanhartesveldt, C., & Joyce, J. N. (1986). EFFECTS OF ESTROGEN ON THE BASAL GANGLIA. *Neuroscience and Biobehavioral Reviews*, 10(1), 1-14. Retrieved from
<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1986A633300001> doi:10.1016/0149-7634(86)90029-1

220.

- # Joyce, J. N., Loeschen, S. K., & Marshall, J. F. (1985). DOPAMINE-D-2 RECEPTORS IN RAT CAUDATE-PUTAMEN - THE LATERAL TO MEDIAL GRADIENT DOES NOT CORRESPOND TO DOPAMINERGIC INNERVATION. *Brain Research*, 338(2), 209-218. Retrieved from
<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1985AMS4500002> doi:10.1016/0006-8993(85)90149-0

145.

- # Joyce, J. N., & Marshall, J. F. (1985). STRIATAL TOPOGRAPHY OF D-2 RECEPTORS CORRELATES WITH INDEXES OF CHOLINERGIC NEURON LOCALIZATION. *Neuroscience Letters*, 53(1), 127-131. Retrieved from
<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1985ACF3600021> doi:10.1016/0304-3940(85)90108-9

60.

- # Rowland, N., Joyce, J. N., & Bellush, L. L. (1985). STEREOTYPED BEHAVIOR AND DIABETES-MELLITUS IN RATS - REDUCED BEHAVIORAL-EFFECTS OF AMPHETAMINE AND APOMORPHINE AND REDUCED INVIVO BRAIN BINDING OF H-3 SPIROPERIDOL. *Behavioral Neuroscience*, 99(5), 831-841. Retrieved from
<http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1985ACF3600021>

=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1985ASJ7900004 doi:10.1037/0735-7044.99.5.831

35.

- # Joyce, J. N., Montero, E., & Vanhartesveldt, C. (1984). DOPAMINE-MEDIATED BEHAVIORS - CHARACTERISTICS OF MODULATION BY ESTROGEN. *Pharmacology Biochemistry and Behavior*, 21(5), 791-800. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1984TR36200020>

21.

- # Joyce, J. N., & Vanhartesveldt, C. (1984). BEHAVIORS INDUCED BY INTRASTRIATAL DOPAMINE VARY INDEPENDENTLY ACROSS THE ESTROUS-CYCLE. *Pharmacology Biochemistry and Behavior*, 20(4), 551-557. Retrieved from [http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1984SL10200012 doi:10.1016/0091-3057\(84\)90304-6](http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1984SL10200012 doi:10.1016/0091-3057(84)90304-6)

32.

- # Joyce, J. N., & Vanhartesveldt, C. (1984). ESTRADIOL APPLICATION TO ONE STRIATUM PRODUCES POSTURAL DEVIATION TO SYSTEMIC APOMORPHINE. *Pharmacology Biochemistry and Behavior*, 20(4), 575-581. Retrieved from [http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1984SL10200015 doi:10.1016/0091-3057\(84\)90307-1](http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1984SL10200015 doi:10.1016/0091-3057(84)90307-1)

40.

- # Joyce, J. N., & Vanhartesveldt, C. (1984). ROTATION AND POSTURAL DEVIATION ELICITED BY MICROINJECTIONS OF DOPAMINE INTO MEDIAL AND LATERAL REGIONS OF DORSAL STRIATUM. *Pharmacology Biochemistry and Behavior*, 21(6), 979-981. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord& UT=WOS:A1984TZ67800026>

18.

- # Joyce, J. N., Davis, R. E., & Vanhartesveldt, C. (1983). SYSTEMIC APOMORPHINE REVERSES INTRASTRIATAL DOPAMINE-INDUCED CONTRALATERAL DEVIATION. *European Journal of Pharmacology*, 87(2-3), 283-289. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action>

=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1983QE81700013 doi:10.1016/0014-2999(83)90339-4

5.

- # Joyce, J. N., Smith, R. L., & Vanhartesveldt, C. (1982). ESTRADIOL SUPPRESSES THEN ENHANCES INTRACAUDATE DOPAMINE-INDUCED CONTRALATERAL DEVIATION. *European Journal of Pharmacology*, 81(1), 117-122. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1982NX92600014> doi:10.1016/0014-2999(82)90608-2

25.

- # Joyce, J. N., Davis, R. E., & Vanhartesveldt, C. (1981). BEHAVIORAL-EFFECTS OF UNILATERAL DOPAMINE INJECTION INTO DORSAL OR VENTRAL STRIATUM. *European Journal of Pharmacology*, 72(1), 1-10. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1981LW11400001> doi:10.1016/0014-2999(81)90290-9

46.

Invited Journal Articles

- # Joyce, J. N. (1992). Monoamine receptors, limbic pathology and schizophrenia. *Clinical neuropharmacology*, 15 Suppl 1 Pt A, 502A-503A. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=MEDLINE:1323403>

0.

Refereed Books

- # Joyce, J. N., & Hurtig, H. I. (1994). *Neurodegenerative Disorders. In: Biological Bases of Brain Function and Disease, Chapter 23*. Raven Press. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI199497053154>

PP 425-448, Raven Press, New York, 1993.

Refereed Book Chapters

- # Joyce, J. N. (2001). Chapter 48: The Basal Ganglia Dopaminergic Systems in Normal Aging and Parkinson's Disease. In P.R. Hof, C.V. Mobbs (Ed.), *Functional Neurobiology of Aging* (pp. 689-709). San Diego: Academic Press.

- # Joyce, J. N., & Gurevich, E. V. (1999). D-3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. In McGinty, J. F. (Ed.), *Advancing from the Ventral Striatum to the Extended Amygdala: Implications for Neuropsychiatry and Drug Abuse: in Honor of Lennart Heimer* (pp. 595-613). M.F. McGinty, (Ed), Annals of the New York Academy of Science. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:000081586500034>
- Conference on Advancing from the Ventral Striatum to the Extended Amygdala - Implications for Neuropsychiatry and Drug Abuse-In Honor of Lennart Heimer 18-21, 1998 rlottesville, virginia Acad Sci; Natl Inst Mental Hlth; E Carolina Univ, Sch Med, Off Res & Grad Studies; Univ Virginia Hlth Sci Ctr; Hoechst Marion Rousell Inc; Merck Res Labs; Pfizer Inc; Pharmacia & Upjohn; Res Biochem Inc; Univ WI Hlth Emot Res Inst 7-8923.
- # Joyce, J. N., & Murray, A. (1994). Chapter 16: Distribution of D1 and D2-like dopamine receptors in human brain. In Hyman B. Niznik (Ed.), *Dopamine Receptors and Transporters* (pp. 345-382). New York: Marcel Dekker, Inc.
- # Joyce, J. N., Goldsmith, S., & Murray, A. (1993). Chapter 2: Neuroanatomical localization of D-1 vs D-2 receptors: similar organization in the basal ganglia of the rat, cat and human and disparate organization in the cortex and limbic system. In J.L. Waddington (Ed.), *Dopamine Receptor Interactions* (pp. 23-49). Academic Press Limited, Harcourt Brace Jovanovich.
- # Joyce, J. N., & Hurtig, H. I. (1993). Chapter 23: Neurodegenerative Disorders. In A. Frazer, P. Molinoff, A. Winokur (Ed.), *Biological Bases of Brain Function and Disease* (pp. 425-448). New York: Raven Press.
- # Joyce, J. N., & Neal-Beliveau, B. (1993). Developmental plasticity of dopamine systems: Pre- and post-synaptic components of the dopamine system are modified by neonatal lesions. In Percheron, G., McKenzie, J. S., & Feger, J. (Eds.), *Advances in Behavioral Biology; The basal ganglia IV: New ideas and data on structure and function* (pp. 137-148). London: Plenum Press, Inc. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI199598292184>
- Fourth Triennial Meeting of the International Basal Ganglia Society ober 5-9, 1992 ns, France 9-6246.
- # Joyce, J. N., Emerich, D. F., Norman, A. B., & Sandberg, P. R. (1991). REGULATION AND ASSESSMENT OF RECEPTORS FOLLOWING TRANSPLANTS. In *Methods in Neurosciences* (pp. 456-477). San Diego, CA: Conn, Academic Press. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI199242114664>
- Ed. 3-9471 Volume 7, ed. P. M. Conn, Academic Press, San Diego, CA.

- # Joyce, J. N., Hensler, J. G., & Tejani-Butt, S. M. (1991). NEUROCHEMICAL LESIONING TECHNIQUES FOR ASSESSING REGULATION OF MONOAMINE RECEPTORS. In *Methods in Neurosciences* (pp. 216-240). P. M. Conn, Academic Press, San Diego, CA. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI199242114650>
Ed. 3-9471 Volume 7, ed. P. M. Conn, Academic Press, San Diego, CA, PP. 216-240, 1991.
- # Joyce, J. N., & Hurtig, H. (1990). DIFFERENTIAL REGULATION OF STRIATAL DOPAMINE D1 AND D2 RECEPTOR SYSTEMS IN PARKINSON'S DISEASE AND EFFECTS OF ADRENAL MEDULLARY TRANSPLANT. In *Neural Transplantation: From Molecular Basis to Clinical Application* (pp. 82:699-706, 1990). Prog. Brain Res. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI199141113750>
Ed.
- # Joyce, J. N., Lexow, N., Neal, B., Hurtig, H., Trojanowski, J. Q., & Winokur, A. (1989). A. Receptor autoradiographic studies in neurodegenerative disorders of the basal ganglia. In A.R. Crossman and M.A. Sambrook (Ed.), *Neural Mechanisms in Disorders of Movement* (pp. 303-312). John Libbey & Company.
- # Joyce, J. N., Gibbs, R. B., Cotman, C. W., & Marshall, J. F. (1988). REGULATION OF ACETYLCHOLINE MUSCARINIC RECEPTORS BY EMBRYONIC SEPTAL GRAFTS SHOWING CHOLINERGIC INNERVATION OF HOST HIPPOCAMPUS. In D.M. Gash, J.R. Sladek Jr. (Ed.), *Transplantation into the Mammalian CNS* (pp. 109-116). New York: Elsevier Science Publishers B.V. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1988T512600014>
3, Progress in Brain Research.
- # Marshall, J. F., & Joyce, J. N. (1988). BASAL GANGLIA DOPAMINE RECEPTOR AUTORADIOGRAPHY AND AGE-RELATED MOVEMENT DISORDERS. In J. Joseph (Ed.), *Central Determinants of Age-Related Declines in Motor Function* (pp. 215-225). ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI198936084355>
Ed. -8923.

- # Altar, C. A., Joyce, J. N., & Marshall, J. F. (1986). FUNCTIONAL ORGANIZATION OF DOPAMINE AND SEROTONIN RECEPTORS IN THE RAT FOREBRAIN. In Boast, C.A., Snowhill, E. and Altar, C.A. (Ed.), *Boast, C. a., E. W. Snowhill and C. a. Altar* (pp. 53-78). New York, New York: Alan R. Liss. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=BCI:BCI198631072559>
Ed. 6-4563.

Invited Reviews

- # Joyce, J. N., & Millan, M. J. (2007). Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. *Curr Opin Pharmacol*, 7(1), 100-5. doi:10.1016/j.coph.2006.11.004
Joyce, Jeffrey N lan, Mark J rnal Article iew land r Opin Pharmacol. 2007 Feb;7(1):100-5. Epub 2006 Dec 13.
- # Joyce, J. N. (1983). MULTIPLE DOPAMINE-RECEPTORS AND BEHAVIOR. *Neuroscience and Biobehavioral Reviews*, 7(2), 227-256. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1983QR46900005>
111.

Refereed Reviews

- # Rogers, J., Mastroeni, D., Leonard, B., Joyce, J. N., & Grover, A. (2007). Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? *Int Rev Neurobiol*, 82, 235-246. Retrieved from [https://doi.org/10.1016/S0074-7742\(07\)82012-5](https://doi.org/10.1016/S0074-7742(07)82012-5)
- # Joyce, J. N., & Millan, M. J. (2005). Dopamine D3 receptor antagonists as therapeutic agents. *Drug Discov Today*, 10(13), 917-25. doi:10.1016/s1359-6446(05)03491-4
Joyce, Jeffrey N lan, Mark J rnal Article earch Support, Non-U.S. Gov't iew land g Discov Today. 2005 Jul 1;10(13):917-25.
- # Joyce, J. N., Goldsmith, S. G., & Gurevich, E. V. (1997). Limbic circuits and monoamine receptors: Dissecting the effects of antipsychotics from disease processes. *Journal of Psychiatric Research*, 31(2), 197-217. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1997XP63700004> doi:10.1016/s0022-3956(96)00043-x
24.

- # Joyce, J. N., Frohna, P. A., & NealBeliveau, B. S. (1996). Functional and molecular differentiation of the dopamine system induced by neonatal denervation. *Neuroscience and Biobehavioral Reviews*, 20(3), 453-486. Retrieved from <http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord&UT=WOS:A1996VH10900008>
- 31.

Refereed Reports

- # Joyce, J. N. (2013). *Mental Health Retrosight: Understanding the returns from research (lessons from schizophrenia)* (Policy Report). Rand Corporation. Retrieved from HTTP://WWW.RAND.ORG/PUBS/RESEARCH_REPORTS/RR325.HTML

Nonrefereed Reviews

- # Joyce, J. N., & Gurevich, E. V. (1999). The dopamine D3 receptor: From neuroanatomy to neuropsychiatry. *NeuroScience News*, 2, 11-21.

Presentations

Invited Keynote and Plenary Presentations at Conferences

For invited keynote and plenary presentations at conferences, 100.0% were regional in scope.

- # Joyce, J. N. (presented 2015, March). *The Research Enterprise and Administration Through the Prism of Four Different Institutions*. Keynote presentation at 2015 Midwest/Western Section Meeting, SRAInternational, Westin Kansas City at Crowne Center, Kansas City, MO. (Regional)
- # Joyce, J. N. (presented 2015, March). *The Research Enterprise and Administration Through the Prism of Four Different Institutions*. Keynote presentation at 2015 Midwest/Western Section Meeting, SRAInternational, Kansas City, MO. (Regional)

Invited Presentations at Conferences

For invited presentations at conferences, 46.7% were international, 46.7% were national, 6.7% were regional in scope.

- # Joyce, J. N. (presented 2005, November). *Mechanisms of Neuroprotection by Dopamine Agonists in Parkinson's Disease*. Presentation at Neurotoxicity Society Satellite

Meeting Dopamine Oxidation and Parkinson's disease, Neurotoxicity Society,
Washington, D.C. (Regional)

- # Joyce, J. N. (presented 2004, December). *D3 receptor-mediated intracellular pathways for neuroprotection against the Parkinson toxin 1-methyl-4-phenylpyridinium (MPP+)*. Presentation at 43rd ACNP Annual Meeting, ACNP, San Juan, Puerto Rico. (International)

Panel Speaker.

- # Joyce, J. N. (presented 2004, December). *Therapeutic role of D3 receptor drugs in schizophrenia, neuroprotection, and drug addiction*. Presentation at The 43rd ACNP Annual Meeting, ACNP, San Juan, Puerto Rico. (International)

Chair, Panel.

- # Joyce, J. N. (presented 2004, May). *Mechanisms of cell death by toxins in terminally differentiated SH-SY5Y cells and neuroprotection by dopamine agonists*. Presentation at Barrow Neurologic Institute Neuroscience Conference, Barrow Neurologic Institute, Phoenix, AZ. (National)

- # Joyce, J. N. (presented 2003, September). *The dopamine D3 receptor and its ligands: Therapeutic implications*. Presentation at 16th European College of Neuropsychopharmacology Congress, College of Neuropsychopharmacology, Prague, Czech Republic. (International)

- # Joyce, J. N. (presented 1998, October). *D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics*. Presentation at New York Academy of Sciences Conference, Advancing From the Ventral Striatum to the Extended Amygdala: Implications for Neuropsychiatry and Drug Abuse, New York Academy of Sciences, Charlottesville, Virginia. (National)

- # Joyce, J. N. (presented 1997, May). *Prefrontal cortex and serotonin in schizophrenia: effects of antipsychotic treatment*. Presentation at 1997 Annual Meeting, Society for Biological Psychiatry, San Diego, CA. (National)

Ziskind-Somerfeld Research Awardee.

- # Joyce, J. N. (presented 1995, December). *Dopamine D3 receptors: From Molecules to Medicine*. Presentation at 34th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico. (National)

Panel Chair.

- # Joyce, J. N. (presented 1994, December). *Dopamine D3 receptors labeled with [125I]trans-7-0H-PIPAT are elevated in schizophrenic brain and decreased by neuroleptic treatment. Panel: The new dopamine receptors: Is there something new in the neuropathology of*

schizophrenia? D3-D5 receptors. Presentation at 33rd Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico. (National)

- # Joyce, J. N. (presented 1993, December). *Anatomy of the 5-HT_{1A} receptor and 5-HT transporter ([125I]RTI-55 and [3H]paroxetine) in human brain: alterations in schizophrenia*, Panel: *5-HT_{1A} receptor: molecular regulation, endocrine control and schizophrenia*. Presentation at 32nd Annual Meeting, American College of Neuropsychopharmacology, Honolulu, Hawaii. (National)
- # Joyce, J. N. (presented 1993, January). *Therapeutics of Parkinson's disease: new insights into old questions*. Presentation at the meeting of Twenty-Sixth Annual Winter Conference on Brain Research, Whistler, BC, Canada. (International)
- # Joyce, J. N. (presented 1992, December). *Characterization of the binding of [125I]epidepride and [125I]NCQ 298 binding to D2 and D3-like dopamine receptors in human brain*. Presentation at the meeting of American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico. (National)
Panel "PET Studies of Dopamine Function".
- # Joyce, J. N. (presented 1992, October). *Damage to the early developing dopamine system permanently alters the matrix-directed dopamine system*. Presentation at the meeting of International Basal Ganglia Society Meetings, Giens-Hymeres, France. (International)
- # Joyce, J. N. (presented 1992, June). *Monoamine receptors, limbic pathology and schizophrenia*. Presentation at the meeting of , Symposia "New Neuropathological Findings in Schizophrenia," Collegium Internationale NeuroPsychopharmacologicum XVIIIth Annual Meeting, Nice, France. (International)
- # Joyce, J. N. (presented 1992, January). *Age dependence of the neurochemical and behavioral effects of damage to the dopamine system*. Presentation at the meeting of Winter Conference on Developmental Psychobiology, Cancun, Mexico. (International)

Invited Presentations at Symposia

For invited presentations at symposia, 80.0% were international, 20.0% were national in scope.

- # Joyce, J. N. (presented 1999, October). *Distribution and regulation of D3 receptors in Parkinson's Disease*. In *6th National Parkinson Foundation International Symposium on Parkinson's Research*. Presentation at the meeting of National Parkinson Foundation, Miami, Florida. (International)
- # Joyce, J. N. (presented 1998, October). *Segregation and co-expression of D2 and D3 receptors in the brain of schizophrenic patients: postmortem studies*. In *Symposia: The Dopamine Hypothesis of Schizophrenia Revisited*. Presentation at the meeting of European College of Neuropsychopharmacology, Paris, France. (International)

- # Joyce, J. N. (presented 1997, June). Dopamine receptors in human brain. In *XVIIIth International Symposium on Cerebral Blood Flow & Metabolism*. Presentation at the meeting of The International Society of Cerebral Blood Flow and Metabolism, Baltimore, MD. (International)
- # Joyce, J. N. (presented 1992, May). Developmental Plasticity of Dopamine Systems. In *7th International Catecholamine Symposium*. Presentation at the meeting of International Catecholamine Symposium, Amsterdam, The Netherlands. (International)
- # Joyce, J. N. (presented 1992, May). Monoamines, limbic pathology and schizophrenia. In *Dopamine and Serotonin Interactions in Schizophrenia Symposia*. Presentation at the meeting of American Psychiatric Association 14th Annual Meeting, Washington, D.C. (National)

Invited Workshops

For invited workshops, 33.3% were international, 66.7% were national in scope.

- # Joyce, J. N. (2006, May). *DA neuron death initiated by DNA damage and protection by D3 preferring agonists*. Workshop delivered at Plasticity and Repair in Neurodegenerative Disorders Workshop, Lake Arrowhead, California. (National)
- # Joyce, J. N. (2003, February). *Dopamine D3 partial agonists as therapeutic target in PD*. Workshop delivered at Expert Workshop in Therapeutic Targets for Treatment of Parkinson's Disease and Related Disorders, New York, NY, SCHWARZ Biosciences. (National)
- # Joyce, J. N. (2000, May). *The dopamine D3 receptor from neuroanatomy to potential target for antipsychotic drugs*. Workshop delivered at Workshop: Schizophrenia: Pathological Bases and Mechanisms of Antipsychotic Action, Chicago, IL. (International)

Invited Lectures and Readings of Original Work

For invited lectures and readings of original work, 7.5% were international, 2.5% were regional, 2.5% were state, 87.5% were local in scope.

- # Joyce, J. N. (2014, June). *Biomedical Research and Collaboration*. Delivered at MRIGlobal, Kansas City, MO. (International) Retrieved from <http://www.mriglobal.org/Blog/Post/110/Dr--Jeffrey-N--Joyce-to-Speak-on-Biomedical-Research,-Collaboration-at-MRIGlobal>
- # Joyce, J. N. (2006, December). *Loss of clinical response to antiparkinsonian drugs (APDs) and the DA D3 receptor*. Delivered at Grand Rounds, Department of Neurology, University of Arizona Medical Center, Tucson, AZ. (Local)

- # Joyce, J. N. (2005, September). *DNA damage and cell death in PD*. Delivered at Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma. (Local)
- # Joyce, J. N. (2005, May). *Can we slow down the progression of Parkinson's Disease?* Delivered at CME Grand Rounds, Sun Health /St Joseph's Geriatric Fellowship Program, Boswell Hospital, Sun City, AZ. (Local)
- # Joyce, J. N. (2005, February). *Mechanisms of Neuroprotection by Dopamine Agonists in Parkinson's Disease*. Delivered at Cellular and Molecular Pharmacology Rosalind Franklin University of Medicine & Science, North Chicago, IL. (Local)
- # Joyce, J. N. (2004, May). *Mechanisms of Neuroprotection Using Antiparkinsonian Agents*. Delivered at Wyeth Research, Princeton, NJ. (Local)
- # Joyce, J. N. (2004, March). *Mechanisms of neuroprotection for D3 agonists in Parkinson's disease*. Delivered at Eli Lilly and Company, Indianapolis, IN. (Local)
- # Joyce, J. N. (2003, September). *Mechanisms of neuroprotection for D3 agonists in Parkinson's disease*. Delivered at Intitut de Recherches Servier, Suresnes, France. (International)
- # Joyce, J. N. (2003, August). *Mechanisms of neuroprotection for D3 agonists in Parkinson's disease*. Delivered at The Parkinson's Disease Task Force, University of California at Irvine, Irvine, CA. (Local)
- # Joyce, J. N. (2002, September). *Neuroprotective properties of D3 agonists in vitro and in vivo*. Delivered at Pharmacology Department, University of North Texas Health Science Center, Fort Worth, TX. (Local)
- # Joyce, J. N. (2002, September). *Neuroprotective properties of pramipexole in vitro and in vivo*. Delivered at Pharmacology Department, Pharmacia Corporation, Kalamazoo, MI. (Local)
- # Joyce, J. N. (2002, May). *Neuroprotection by D3 preferring agonists: basic and clinical research*. Delivered at Pharmacology Department, University of San Antonio, San Antonio, TX. (Local)
- # Joyce, J. N. (2002, April). *The dopamine D3 receptor as a therapeutic target for antipsychotic drugs*. Delivered at Pfizer Pharmaceuticals, Groton, CT. (Local)
- # Joyce, J. N. (2001, April). *Neuroprotection by Antiparkinsonian Drugs: basic and clinical research*. Delivered at Arizona State University, Tempe AZ. (Local)
- # Joyce, J. N. (2001, April). *The dopamine D3 receptor as a therapeutic target for antiparkinsonian drugs*. Delivered at University of Tennessee, Department of Pharmacology, Memphis, TN. (Local)

- # Joyce, J. N. (2000, May). *The dopamine D3 receptor: from neuroanatomy to potential target for antiparkinsonian drugs*. Delivered at Unité de Recherche en Neurosciences, Centre de Recherche, Center Hospitalier Universitaire du Québec, Québec, Canada. (Regional)
- # Joyce, J. N. (2000, May). *The dopamine D3 receptor: from neuroanatomy to potential target for antiparkinsonian drugs*. Delivered at Rush University, Department of Pharmacology, Chicago, IL. (Local)
- # Joyce, J. N. (2000, January). *The dopamine D3 receptor from neuroanatomy to potential target for antiparkinsonian drugs*. Delivered at The Parkinson's Institute, Sunnvale, CA. (Local)
- # Joyce, J. N. (1999, March). *The dopamine D3 receptor: from neuroanatomy to neuropsychiatry*. Delivered at The Department of Pharmacology, The University of Texas Health Science Center, San Antonio, Texas. (Local)
- # Joyce, J. N. (1998, September). *Extrapyramidal symptoms in Alzheimer's disease: Underlying mechanisms*. Delivered at Molecular and Cellular Biology Lecture Series, Arizona State University, Tempe, AZ. (Local)
- # Joyce, J. N. (1998, July). *Dopamine D3 receptors: Ontogeny and alterations in schizophrenia*. Delivered at DA '98, Strasbourg, France. (Local)
- # Joyce, J. N. (1998, July). *Extrapyramidal symptoms in Alzheimer's disease: Underlying mechanisms*. Delivered at Molecular and Cellular Biology Lecture Series, University of Manchester, Manchester, England. (Local)
- # Joyce, J. N. (1998, April). *Dopamine D3 receptor as a target of antipsychotics*. Delivered at Neurosciences Program, University of Michigan, Ann Arbor, MI. (Local)
- # Joyce, J. N. (1997, April). *Prefrontal cortex serotonin and the mesolimbic dopamine system: sites for antipsychotic action*. Delivered at Wyeth-Ayerst Pharmaceutical, CNS Division, Princeton, NJ. (Local)
- # Joyce, J. N. (1996, May). *Parkinsonian Symptoms in Alzheimer's Disease: A Different Neuropathology*. Delivered at Department of Neurology, Rush-Presbyterian, Chicago, Illinois. (Local)
- # Joyce, J. N. (1995, April). *Differential loss of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of Parkinson's, Alzheimer with parkinsonism and Alzheimer's disease*. Delivered at Neurodegenerative Disorders: Common Molecular Mechanisms, Ocho Rios, Jamaica. (International)

- # Joyce, J. N. (1994, October). *Novel dopamine receptors and their role in schizophrenia*. Delivered at Department of Psychiatry, Wayne State University, Detroit, MI. (Local)
- # Joyce, J. N. (1994, September). *Developmental sequelae of the mesostriatal dopamine system and alterations by dopamine depletion*. Delivered at Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA. (Local)
- # Joyce, J. N. (1994, July). *Anatomy of novel dopamine receptors in human brain and their alterations in schizophrenia*. Delivered at Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA. (Local)
- # Joyce, J. N. (1994, July). *Schizophrenia and monoaminergic systems: postmortem studies implicate convergent effects in ventral striatum and divergent effects in medial temporal lobe*. Delivered at Department of Psychiatry, Mailman Research Center, McLean Hospital, Harvard University, Boston MA. (Local)
- # Joyce, J. N. (1994, June). *Dopamine D2 and D3 receptors are altered in schizophrenia: Implications for treatment*. Delivered at Division of Molecular Biology and Division of Central Nervous System Joint sponsor, WyethAyerst Pharmaceuticals, Princeton, N.J. (Local)
- # Joyce, J. N. (1994, June). *Novel Dopamine Systems in Human Brain: Implications for Understanding Neuropsychiatric and Neurodegenerative Disorders*. Delivered at Department of Radiology, Brigham and Women's Hospital, Harvard University, Boston MA. (Local)
- # Joyce, J. N. (1994, May). *Meso striatal and Mesolimbic Dopamine Systems in Neurodegenerative Disorders*. Delivered at Department of Pharmacology, Texas Tech University Health Sci Ctr, Lubbock, TX. (Local)
- # Joyce, J. N. (1994, April). *Novel Dopamine Receptors: Alterations in Alzheimer's Disease*. Delivered at Sun Health Research Center, Sun City, AZ. (Local)
- # Joyce, J. N. (1994, April). *Novel Dopamine Systems in Human Brain: Implications for Understanding Schizophrenia*. Delivered at UpJohn Pharmaceuticals, Kalamazoo, MI. (Local)
- # Joyce, J. N. (1992, November). *An anatomical basis for monoamine interactions in schizophrenia*. Delivered at Department of Psychiatry, Mount Sinai School of Medicine, New York. (Local)
- # Joyce, J. N. (1992, October). *Developmental plasticity of the dopamine system: role of dopamine as a neurotrophin*. Delivered at Junior Faculty Scholars Program, The Rockefeller University, New York, N.Y. (Local)

- # Joyce, J. N. (1992, September). *The role of dopamine in receptor expression differs in the neonate and the adult*. Delivered at Department of Pharmacology, Temple University, Philadelphia, PA. (Local)
- # Joyce, J. N. (1992, February). *Developmental dopamine plasticity*. Delivered at Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, PA, Pennsylvania, Philadelphia, PA. (State)
- # Joyce, J. N. (1992, February). *Monoamine receptors, limbic pathology and schizophrenia*. Delivered at Neuroscience Program Seminar Series, University of Illinois, Urbana-Champaign, IL. (Local)

Contracts and Grants

Contracts and Grants In Review

Contracts and Grants Funded

- Joyce, Jeffrey Neal (PI) (June 2019-May 2024) *Together: Transforming and Translating Discovery to improve Health*. Awarded to University of Florida. A UF-FSU partnership, FSU subcontract of \$3,474,750 (direct). Received a CTSA priority score of 20, awarded April 1, 2019
- Joyce, Jeffrey Neal (PI). (Oct 2017–Sep 2018). *OneFlorida Clinical Research Consortium*. Funded by University of Florida. (UFDSP00012063). Total award \$239,258.
- Muszynski, Michael J (Co-PI), & Joyce, Jeffrey (PI). (Apr 2017–Mar 2018). *Together: Transforming and Translating Discovery to improve Health*. Funded by University of Florida. (UFDSP00011722). Total award \$228,000.
- # Muszynski, Michael J (PI), & Joyce, Jeffrey Neal (Co-PI). (Oct 2016–Sep 2017). *OneFlorida Clinical Research Consortium*. Funded by University of Florida. (UFDSP00011651). Total award \$610,289.
 - # Muszynski, Michael J (Co-PI), & Joyce, Jeffrey (PI). (Apr 2016–Mar 2017). *Together: Transforming and Translating Discovery To Improve Health*. Funded by University of Florida. (UFDSP00011299). Total award \$228,000.
 - # Muszynski, Michael J (Co-PI), & Joyce, Jeffrey (PI). (May 2015–Mar 2018). *Together Transforming and Translating Discovery to Improve Health*. Funded by University of Florida. (UFDSP00011030). Total award \$648,836.
 - # Beitsch, Leslie (Co-PI), Muszynski, Michael J (Co-PI), & Joyce, Jeffrey (PI). (Oct 2014–Jun 2017). *OneFlorida Cancer Control Network*. Funded by University of Florida. (1500355347). Total award \$229,370.

- # Joyce, J. N. (Oct 2005–Jun 2008). *Prevention of Progression to Parkinson's Disease and Parkinson's Disease with Dementia: Development of Biomarkers and Treatment Strategies: Project 1 (Joyce): "Deficient Levels of BDNF in Cortical Neurons of Parkinson's Disease with Dementia"*. Funded by Arizona Biomedical Research Commission. Total award \$150,000.
ABRC Center Project contract number 0011.
- # Joyce, J. N. (Apr 2004–Sep 2004). *Neuroprotective effects of S38646 as compared to reference compounds in Parkinsonian models*. Funded by Institute de Recherches Servier, France. Total award \$76,800.
- # Neisewander, J., & Joyce, J. N. (Jan 2004–Jun 2007). *Limbic-cortical involvement in drug-seeking. Subcontract: Gene expression profiling of cocaine's effects*. Funded by NIDA. (1R01 DA13649-03). Total award \$225,000.
Federal subcontract.
- # Joyce, J. N. (Mar 2003–Feb 2004). *DA agonist neuroprotection via Akt pathway in MPTP mouse model of Parkinson's*. Funded by The Michael J. Fox Foundation for Parkinson's Research. Total award \$50,000.
- # Joyce, J. N. (Sep 2002–Mar 2003). *Neuroprotection afforded by topiramate in models of Parkinson's*. Funded by RW Johnson PRI (New Jersey). Total award \$60,000.
- # Joyce, J. N. (Sep 2001–Jun 2004). *Arizona Disease Control Research Commission*. Funded by Arizona Parkinson's Disease Center. Total award \$5,500,000.
ADRC contract 4001.
- # Joyce, J. N. (Jan 2001–Sep 2002). *Neuroprotective effects of S32504 as compared to reference compounds in Parkinsonian models*. Funded by Institute de Recherches Servier, France. Total award \$76,800.
- # Joyce, J. N. (Jul 2000–Jun 2003). *Mesolimbic Dopamine D3 Receptor and Parkinson's Disease*. Funded by NINDS. (5R01 NS40699). Total award \$1,129,533.
- # Joyce, J. N. (Dec 1998–Mar 2001). *Effects of pramipexole on cell death using the neuroblastoma cell line SH-SY5Y in response to MPP+*. Funded by Pharmacia Corporation, Kalamazoo MI. Total award \$45,000.
- # Reiman, E., & Joyce, J. N. (Jul 1998–Jun 2002). *Arizona Alzheimer's Disease Research Center Subproject: Antemortem and postmortem differentiation of Lewy body disease*. Funded by State of Arizona AZDHS. Total award \$360,000.
- # Joyce, J. N. (Mar 1998–Dec 1994). *[3H]Paroxetine binding to human brain*. Funded by SmithKline Beechum, United Kingdom (GlaxoSmithKline). Total award \$75,000.

- # Joyce, J. N. (Jan 1997–Mar 1998). *[3H]Prasopexole binding to D3 receptors in human brain*. Funded by Pharmacia Corporation, Kalamazoo MI. Total award \$45,000.
- # Joyce, J. N. (Sep 1996–Aug 1998). *Disturbed patterns of D2 receptor mRNA expressing neurons in the temporal lobe of schizophrenics*. Funded by Scottish Rite Schizophrenia Research Program. Total award \$75,000.
THE SUPREME COUNCIL 33°, SCOTTISH RITE.
- # Joyce, J. N. (Jul 1996–Jun 1999). *Mesolimbic DA D3 Receptor and Schizophrenia*. Funded by NIMH. (5R01 MH 56824-01). Total award \$523,617.
- # Joyce, J. N., & Trojanowski, J. (May 1996–Apr 2003). *Molecular Substrates of Aging and Neuron Death, Project 1: Degeneration of Dopaminergic Pathways*. Funded by NIA. (5P01 AG09215). Total award \$945,000.
- # Joyce, J. N. (Aug 1993–Jul 1995). *Limbic Dopamine Receptors*. Funded by Scottish Rite Schizophrenia Research Program. Total award \$75,000.
THE SUPREME COUNCIL 33°, SCOTTISH RITE.
- # Joyce, J. N. (Jul 1993–Jun 1996). *Developmental Plasticity of Dopamine Systems*. Funded by NIMH. (5R01 MH 48813-01A2). Total award \$350,000.
- # Gur, R. E., & Joyce, J. N. (Jul 1991–Jun 1996). *Regional Brain Function in Schizophrenia Core VI. Neuropharmacology*. Funded by NIMH. (P50 MH 43880). Total award \$1,850,642.
- # Gennarelli, T., & Joyce, J. N. (Apr 1991–Mar 1994). *Head Injury Clinical Research Center: Project 1: Receptor Changes in Human Head Injury*. Funded by NINDS. (5P01 NS 08803). Total award \$798,365.
- # Joyce, J. N. (Nov 1990–Nov 1991). *Central nervous system distribution, pharmacology and regional effects of SQ29852*. Funded by E.R. SQUIBB & Sons Pharmaceuticals, Princeton, New Jersey (Bristol-Myers Squibb). Total award \$45,000.
- # Joyce, J. N. (Jul 1990–Jun 1991). *Distribution of [3H]CP96,345 binding in post-mortem human brain- A substance P receptor antagonist*. Funded by Pfizer Central Research, Groton CT. Total award \$45,000.
- # Joyce, J. N. (May 1988–Apr 1993). *Neurotransmitter disorders in schizophrenia*. Funded by NIMH. (5R29 MH 48352). Total award \$542,500.
- # Joyce, J. N. (Aug 1987–Jul 1989). *Visualization of Neurochemical and Neuropathological Changes in Post Mortem Schizophrenic Tissue Utilizing Neurotransmitter*

Autoradiography. Funded by Scottish Rite Schizophrenia Research Program. Total award \$40,000.

THE SUPREME COUNCIL 33°, SCOTTISH RITE.

- # Joyce, J. N. (Jul 1987–Jun 1988). *Neurotransmitter Alterations in Aged Striatum*. Funded by American Federation for Aging Research. Total award \$35,000.

AFAR Junior Faculty Research Award.

- # Molinoff, P., & Joyce, J. N. (Apr 1986–Mar 1990). *Pharmacology of Receptor/Effector Systems, Project 5: Regulation of dopamine receptors*. Funded by NIGMS. (5P01GM034781). Total award \$212,000.

Funding for 4 projects (subcontracts) and Core (Brain Donor Program) in Parkinson's disease.

Resource Grant

- # Joyce, J. N. (1991, September–1992, August). A grant of Small Instrumentation Grant. *ADAMHA Small Instrumentation Grant*. Sponsored by ADAMHA.

Awarded for purchase of Reichert Jung Cryostat.

Postdoctoral Supervision

- # Kruman, I. (2001–06).

2001-2006 Staff Scientist, Thomas H. Christopher Center for Parkinson's Disease Research Current Position: Associate Professor, Department of Neuropsychiatry, Garrison Institute on Aging, Texas Tech University Health Sciences Center.

- # Gurevich, E. (1991–95).

1995-2001 Scientist, Thomas H. Christopher Center for Parkinson's Disease Research Current Position: Associate Professor, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN.

- # Rioux, L. (1991–94).

Support: Fonds De La Recherche En Sante Du Quebec (7/01/91 - 3/30/94), Temporal Correlation of mRNA Coding for dopamine Receptors in Different Striatal Compartments as Related to Maturation of Dopamine Afferents, Total Direct Costs: \$53,000 NIB. (4/01/94 - 3/30/95), Substance P Receptors in Parkinson's and Alzheimer's Disease, Total Direct Costs: \$30,000. Current Position: Investigator, Dept Neurobiol & Anat, Drexel University Medical Center, Philadelphia, PA.

- # Murray, A. (1990–92).

Support: National Parkinson Foundation, Inc. (7/01/91 - 6/30/92), Dopamine Receptors in Parkinson's and Alzheimer's Disease, Total Direct Costs: \$40,000. Current Position: Intellectual Patents Advisor, Dublin, Ireland.

Neal-Belliveau, B. (1987–91).

Support: Training Program in Neuropsychopharmacology, Department of Pharmacology, University of Pennsylvania School of Medicine Tourette Syndrome Association (7/1/90 - 6/30/91), Developmental Plasticity of Basal Ganglia Dopamine Systems, Total Direct Costs: \$25,000 National Institute of Mental Health (10/1/90 - 9/30/91), Dopamine Denervation and Receptor Subtype Regulation (F32 MH09888), Total Direct Costs: \$28,000 Current Position: Associate Professor of Psychology, Indiana University, Indianapolis, IN.

Service

Florida State University

FSU University Service

Member, University Task Force for Health Sciences Big Data Institute and Steering Committee (2018–present).

Member, University of Florida Clinical and Translational Science Institute Steering Committee (2017–present). Member, OneFlorida Executive Committee (2018–present).

As part of the OneFlorida Clinical Research Consortium.

Member, Director of Human Subjects Research Search Committee (2019)

FSU College Service

Member, Orlando Regional Dean Search Committee (2019–present).

Chair, LCME Self Study Committee: Institutional Setting/Governance and Administration (2017–2019).

Member, LCME Self Study Committee: Steering Committee (2017–2019).

Member, FSU College of Medicine Compliance Committee (2018–2019).

Chair, FSU Quality Enhancement Review Self Study Committee (2017–2018).

The Profession

Editorial Board Membership(s)

Journal of Research Administration (2013–2015).

Editor-in-Chief.

Journal of Research Administration (2012).

Chair of the Academic Review Board.

Neurotoxicity Research (1998–2007).

Synapse (1992–2004).

Neuropsychopharmacology (1995–2000).

Chair of a Symposium

Joyce, J. N. (Chair). (1998, July). *Molecular substrates of neurochemical disturbances in schizophrenia*. Symposium conducted at the meeting of XXI CINP Congress, Glasgow, Scotland.

Joyce, J. N. (Chair). (1993, May). *Psychosis, Dementia and the Medial Temporal Lobe, 146th Annual Meeting*. Symposium conducted at the meeting of American Psychiatric Association, San Francisco, California.

Reviewer or Panelist for Grant Applications

American Association for the Advancement of Science (AAAS) Research Competitiveness Program (2015–present).

Multidisciplinary Assessment Committee for the Canada Foundation for Innovation (2015–present).

Patient-Centered Outcomes Research Institute (2014–present).

Review Panels: Assessment of Prevention, Diagnosis, and Treatment Options; Large Pragmatic Studies to Evaluate Patient-Centered Outcomes; Chair, Targeted PFA – Treatment of Multiple Sclerosis.

Reviewer for American Health Assistance Foundation (external) (1999–present).

Reviewer for Natural Sciences and Engineering Research Council of Canada (external) (1999–present).

Reviewer for NSF grants (1999–present).

Reviewer for Ontario Mental Health Foundation, Canada (external) (1999–present).

Reviewer for The Wellcome Trust, London, England (external) (1999–present).

Reviewer for Veterans Administration Merit Award (external) (1999–present).

- # Clinical Neuroplasticity and Neurotransmitters [CNNT] study section (2006–2007).
- # Neurodegeneration and the Biology of the Glia Study Section [NDBG (2005–2007).
- # NIA ZAG1 ZIJ-9 (M3) Beeson Career Development- Special Emphasis Panel (2005–2007).
- # VA Merit Review Subcommittee – Chair, Neurobiology D (2003–2007).
- # Reviewer for American Federation for Aging Research (1999–2003).
- # Department of Defense-Neurotoxin Exposure Program review panel (2002).
- # Reviewer for NIMH – Ad Hoc to Review Group NPNC (1995–1998).

Service to Professional Associations

- # Member, Kansas City Area Life Sciences Institute (KCALSI) Institutional Advisory Committee (IAC) (2012–present).
- # Liason Committee member, American College of Neuropsychopharmacology (2006–2009).
- # Finance Committee member, American College of Neuropsychopharmacology (2001–2004).
- # Board Member and Finance Committee Chair, Annual Spring Brain Conference (1997–2000).
- # Chair Finance Committee, International Behavioral Neuroscience Society (1994).
- # Program Chair, International Behavioral Neuroscience (1993).

Service to Other Universities

- # Member, *Stakeholder Engagement Advisory Board (SEAB), Frontiers: The Heartland Institute for Clinical and Translational Research, University of Kansas* (2012–present).
Frontiers: The Heartland Institute for Clinical and Translational Research, University of Kansas.

The Community

- # Executive Steering Committee, CONECTR (Community Oriented Network to Enhance Clinical Trials and Research) an ASU-Quintiles alliance (2010–2012).
- # Board Member, Carl T. Hayden Medical Research Foundation (Phoenix, AZ), associated with the Phoenix VA Health Care System (2009–2012).

Neuroscience Platform Committee, Flinn Foundation – Battelle Commission Bioindustry Roadmap (2001–2006).

Radiation Safety Officer, Sun Health Research Institute (1995–2006).

Professional activities that occurred prior to my employment at FSU.